BACKGROUND: Peritoneal carcinomatosis (PCA) has a prognostic role in patients with gastrointestinal cancers. The differential diagnosis may be challenging due to the low sensitivity of cytology. Although microRNAs (miRNAs) have been a focus of various specimens and diseases, to the best of the authors' knowledge only limited knowledge exists regarding ascites. Herein, the authors systematically evaluated preanalytical factors and the potential of miRNAs as biomarkers of ascites. METHODS: The authors prospectively analyzed samples from patients with PCA, spontaneous bacterial peritonitis (SBP), and portal hypertension (no SBP/PCA). Various preanalytical factors such as extraction kits, sample storage, stability, and processing were systematically evaluated. MiRNA expression profiling using TaqMan Low Density Array and quantitative reverse transcriptase-polymerase chain reaction were used to evaluate miRNA expression. RESULTS: All selected miRNAs were found to be reliably detectable in ascites samples. Ascites miRNAs were well preserved from degradation with required short-term and long-term stability. MiRNA expression profiling in patients with PCA compared with those with no SBP/PCA revealed miR-21, miR-186, miR-222, and miR-483-5p to be upregulated and miR-26b to be downregulated. MiRNA expression validation analysis confirmed higher expression levels of miR-21 and miR-186 in patients with PCA compared with those with no SBP/PCA, whereas miR-223 was significantly upregulated in patients with SBP. A simple proportion score between miR-21 and miR-223 allowed the authors to discriminate between the patients with PCA and those with SBP with an area under the curve of 0.982 (95% confidence interval, 0.943-1.022). CONCLUSIONS: The data from the current study provide novel evidence of the differential expression of miRNAs in ascites from patients with PCA and SBP, which may offer an additional miRNA-based molecular approach for the differential diagnosis of PCA.
INTRODUCTION
Gastrointestinal malignancies are the leading cause of the global cancer burden. 1, 2 Unfortunately, clinical symptoms appear most often at the late stages of disease and therefore are associated with poor patient survival. Some tumors induce diffuse dissemination of the tumor cells into the peritoneal cavity. 3, 4 The appearance of peritoneal carcinomatosis (PCA) is associated with tumor progression and an unfavorable outcome (survival ranging from weeks to months), with ascites and bowel obstruction as the main symptoms. [5] [6] [7] Although novel multimodal treatment strategies, including cytoreductive surgery, hyperthermic intraperitoneal chemotherapy, and systemic chemotherapy, improve patient outcomes, to the best of our knowledge no curative therapy currently is available. 8 Diagnostic management is based on imaging of PCA and cytological evaluation of ascites followed by an invasive approach such as laparoscopy or laparotomy. Computed tomography and magnetic resonance imaging deliver the most reliable results for the nodal type of PCA and predominantly in advanced stages of disease. 4, 9 With the increasing application of multimodal therapy strategies, there also is an increasing number of secondary ascites forms related to portal hypertension, inflammation, hypoalbuminemia, etc. However, cytology remains the gold standard that allows for the definitive diagnosis with high specificity, although the sensitivity is only approximately 40% to 60%. 10 Therefore, it remains a challenge to distinguish patients with PCA from patients with ascites related to benign conditions. In particular, patients with cirrhosis and ascites may develop spontaneous bacterial peritonitis (SBP), which occurs in 10% to 30% of cases. 11 Due to the clinical consequences of the diagnosis, such as potential tumor progression or the need for otherwise specific treatment changes, an accurate diagnosis is highly relevant. 12 Despite intensive research, to the best of our knowledge there has only been limited progress in the development of alternative molecular-based methods for the diagnosis of PCA and SBP. MicroRNAs (miRNAs) are small, endogenous, noncoding RNA molecules with unique biological properties that demonstrate potential as diagnostic, prognostic, predictive biomarkers and furthermore are potential therapeutic targets. 13, 14 MiRNAs have been identified as essential regulators of various physiological and pathological processes by controlling a great number of target messenger RNAs (mRNAs) and consequently influencing the expression of a large number of proteins. [15] [16] [17] [18] The biogenesis of miRNAs is becoming increasingly understood, and has been the focus of several reviews to date. 19, 20 MiRNA is a consequence of the complex transcription and RNA processing. During this process, miRNA binds to Argonaute proteins and controls the gene expression as the RNAinduced silencing complex (RISC). The free miRNA strands undergo rapid degradation and the functional miRNAs (either as part of exosomes or bound to proteins) for the most part can be easily and reproducibly detected in various body fluids such as blood, urine, feces, cerebrospinal fluid, etc.
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Analysis of various tumors in the pivotal article from Lu et al revealed substantial differences in miRNA expression between different entities. 22 It is interesting to note that certain miRNAs such as miR-21 were shown to be deregulated in nearly all types of malignant diseases. 19 Furthermore, miRNA expression patterns have been shown to be specific for certain tumor subgroups within a tumor entity. 23 Although accumulating evidence has indicated the potential use of miRNAs as a biomarker in tumor tissues, blood, urine, and feces, to the best of our knowledge only limited data exist regarding the feasibility of miRNA detection in ascites in this context. Weber et al described the presence of miRNA in ascites within an analysis of the miRNA distribution in several body fluids. 21 Recently,
Tokuhisa et al published their data on miRNA expression in peritoneal lavage fluid and ascites among patients with peritoneal metastasis as a result of gastric carcinoma. 24 Although these authors mainly focused on peritoneal lavage fluid, to the best of our knowledge to date there has no systematic analysis of miRNAs in ascites.
In the current proof-of-principle study, we evaluated the feasibility of miRNA expression analysis in ascites for PCA or peritonitis. We performed a series of systematic analyses on the stability of miRNAs in ascites and evaluated the influence of extraction methods as well as crucial preanalytical factors that may influence the measurements. Subsequently, we used miRNA array-based profiling to identify several miRNAs that demonstrate differential expression in patients with PCA and SBP. Several miRNAs then were validated in independent experiments, thereby suggesting a potential value for miRNAs to serve as a surrogate markers for neoplastic or inflammatory alterations in ascites.
MATERIALS AND METHODS

Ethics
The current prospective study was performed at the Department of Gastroenterology, Hepatology and Infectious Diseases at Otto-von-Guericke-University in Magdeburg, Germany. The study was performed according to the Declaration of Helsinki and ethical principles for medical research involving human subjects. The institutional review board approved the study protocol (85/10) and the participants provided written informed consent before inclusion in the study.
Clinical Samples
The ascites samples (approximately 25 mL) were collected from patients with various conditions during diagnostic or therapeutic paracentesis. For this proof-of-principle study, we prospectively collected ascites specimens from 45 patients meeting the following criteria: 1) 15 , and negative bacterial culture). 9, 11, 25, 26 Detailed characteristics of the patients are provided in Table 1 . In addition, samples from an additional 4 patients with various conditions were used for stability analysis. All unprocessed samples were stored at 2308C until extraction, with the exception of the longterm stability analysis, which was stored at 2808C.
Cytology Diagnosis and Clinical Chemistry
The ascites samples were analyzed by cytology, PMN, and bacterial culture at the pathology, clinical chemistry, and in the medical microbiology departments, respectively at Ottovon-Guericke-University based on clinical routine protocols.
Sample Preparation and Stability Analysis
To evaluate the best sample storage, 1.5 mL of ascites samples was stored both at 2308C and 2808C for up to 2 years until further miRNA extraction or prepared as described below. Ascites samples were centrifuged at 3000 3 g for 10 minutes at 208C to remove cellular debris and the supernatant fluid was stored at 2308C before it was used for miRNA extraction. To create the cell pellets, ascites samples were centrifuged at 10,000 3 g for 5 minutes at 48C and the pellet was stored at 2308C until further miRNA extraction. For stability analysis, 1.5 mL of ascites samples was stored at 2308C when it arrived at the laboratory whereas the sample residue was incubated at room temperature. At each time point after 12 hours, 24 hours, and 48 hours, 1.5 mL of the sample residue again was stored at 2308C and miRNA extraction was performed within 2 to 3 weeks.
RNA Isolation
Total RNA (including miRNAs) was extracted from various ascites samples according to the manufacturer's instructions with minimal modifications. We compared several extraction methods including the miRNeasy Mini Kit (Qiagen, Hilden, Germany), mirVana miRNA Isolation Kit (Life Technologies, Carlsbad, California), or TRIzol Reagent (Life Technologies). For comparison, we used equal amount of ascites (100 lL) and 5 lL of synthetic 5 nM cel-miR-39 was added to every sample for normalization. Briefly, for isolation using the miRNeasy Kit, 100 lL 
Abbreviations: PCA, peritoneal carcinomatosis; SBP, spontaneous bacterial peritonitis group includes patients with spontaneous or secondary bacterial peritonitis without evidence for peritoneal carcinomatosis; portal hypertensions (no SBP/PCA); SD, standard deviation.
of ascites was lysed in QIAzol lysis reagent and the RNA was precipitated using chloroform. The aqueous phase was mixed with 1.5 volume of 100% ethanol. For isolation using the mirVana Kit, 100 lL of ascites was lysed in lysis/ binding buffer, precipitation was performed with acid-phenol:chloroform, and the aqueous phase was mixed with 1.25 volumes of 100% ethanol. For TRIzol-based isolation, we used TRIzol Reagent with chloroform-based precipitation. Aqueous phase was mixed with 1 volume of 100% ethanol. RNA quality was assessed using A260/280 ratios using ultraviolet spectrophotometry and the samples were stored at 2808C until further analysis.
miRNA Profiling by TaqMan Low Density Array
The mature miRNA profiling of ascites from 13 patients with PCA and 10 patients with cirrhosis was performed using the TaqMan Array Human MiRNA Card A v2.1 (Life Technologies), which allowed us to quantify 377 human miRNAs cataloged in miRBase v21. 27 Initially, 3 lL of total RNA purified from ascites was reverse transcribed using the Megaplex RT set pool A version 2.1 (Applied Biosystems, Carlsbad, California); 6 lL of cDNA product, 450 lL of Universal PCR (polymerase chain reaction) Master Mix (Applied Biosystems), and 444 lL of nuclease-free water (Ambion Inc, Carlsbad, California) then were mixed and loaded onto the TaqMan Low Density Array (TLDA), which then was run on the ViiA 7 Real-Time PCR System (Life Technologies). The expression levels in terms of threshold cycle (Ct) values were generated using ViiA 7 Software (Life Technologies) with automatic settings for assigning the baseline. The mature miRNAs with a Ct value >39 in >25% of samples were considered to have low expression and therefore were excluded from further analysis. TLDA expression data were normalized using 2 different methods: delta-delta-Ct (U6 snRNA as reference) and rank-invariant normalizations. 28, 29 Two-class differential expression analysis was performed using the Student t test. The mature miRNAs with a P value <.05 were considered to be significantly differentially expressed. TLDA data analysis was performed using the (Bioconductors) HTqPCR package. 30 MiRNA Quantification by Real-Time PCR
Quantitative miRNA expression analysis was performed using either the SYBR Green method (miR-21) or TaqMan miRNA assays (Life Technologies) according to the manufacturers' instructions. Reverse transcription was performed using the TaqMan miRNA RT Kit (Life Technologies) as follows: 30 minutes at 168C, 30 minutes at 428C, and 5 minutes at 858C. Real-time quantification was performed using the CFX96 real-time PCR Cycler (Bio-Rad Laboratories, Hercules, California). All reactions were run in duplicate and the mean value was used for analysis. We used spiked-in cel-miR-39 for the volume and extraction normalization. RNU6b was evaluated to estimate the potential stability of small RNAs. 31, 32 All reproducible Ct values >40 were considered to be negative. Analyses were performed using the 2
DCt
-method and the data were either presented as the difference between the groups (DCt) or as the relative fold change (2 DCt ) normalized to cel-miR-39.
Statistical Analysis
Statistical analysis was performed using GraphPad Prism 7 (GraphPad Software Inc, La Jolla, California). All data are presented as the mean 6 the standard deviation. The chisquare test and Fisher exact test were used for contingency tables. The Student t test for paired data, the Student t test for unpaired data, and the analysis of variance test were used to analyze the statistical significance for 2 paired/ unpaired groups or multiple groups, respectively. Post hoc analyses were performed using the Holm-Sidak multiple comparisons test. Correlation analyses were performed using the Spearman test. Potential diagnostic performance was evaluated using receiver operating characteristic (analysis defined by the area under the curve). Box and whiskers plots (minimum to maximum) were used to demonstrate the data distribution in figures. Two-sided P values <.05 were considered to be statistically significant.
RESULTS
To evaluate the feasibility of miRNA analysis in ascites, we divided our work into 2 parts. First, we performed the preanalytical evaluation of feasibility of extraction, reproducibility, impact of various extraction methods, specimens, and storage of ascites samples (Fig. 1A) . Second, we performed profiling analysis of miRNAs in clinical specimens; we then validated the data using an independent method.
Extraction and Reproducibility
Given the fact that miRNAs are detectable in human body fluids, feces, and tissues, we explored the presence of miRNAs in ascites. For this, we selected several widely studied miRNAs and small nucleolar RNA RNU6b for our preliminary analysis (Fig. 1B) . Using slightly modified protocols of commercial RNA extraction kits, we were able to isolate a sufficient amount of total RNA and detect miRNAs. To confirm the reproducibility of the analysis and evaluate the differences between extraction methods, we performed a series of experiments using miRNeasy, mirVana, or TRIzol extraction. Each method independently demonstrated very good reproducibility of the miRNA expression (Figs. 1C-1E ). However, if compared between the kits, we observed some differences in performance based on the kit used. MiRNeasy and mirVana extractions provided the most robust and comparable results for miRNA expression analysis (Figs. 1F and 1G ), whereas TRIzol-based extraction was associated with lower Ct values in the current study. However, for RNU6b evaluation, mirVana demonstrated the best values (Fig. 1H) . Based on the ease of performance and slightly higher miRNA detection values, we completed our further work using the miRNeasy kit. However, for future studies, potential differences in miRNA expression between different extraction methods need to be considered.
Stability of Small RNAs
MiRNAs are known to be resistant to degradation in various specimens. To evaluate the stability of miRNAs in ascites and the potential influence of sample delivery time to the laboratory, we performed a series of experiments in which the patient samples proceeded to stability analysis after various waiting times at room temperature. As shown in Figures 2A and 2B , paired analysis revealed comparable miR-16 and RNU6b expression patterns between the time points, suggesting sufficient stability of miRNAs in the ascites samples. The large standard deviation was related to intraindividual variation and not to differences in stability. Next, we evaluated the influence of long-term storage (2308C vs 2808C for 2 years) conditions on the performance of miRNA analysis. Although there was a slight trend toward an increased miR-16 level in samples stored at 2808C, the difference did not reach statistical significance, suggesting that 2308C is sufficient for temporary storage (Figs. 2C and 2D ). In comparison with miR-16, RNU6b values also demonstrated an acceptable stability profile for both 2308C and 2808C; however, the absolute abundance of RNU6b is much lower compared with miR-16 (deltaCt of approximately 6 cycles) and therefore may be prone to greater variation.
miRNA in Different Ascites Specimens
Ascites consist of several components, including cells and transudate or exudate dependent on the conditions. We questioned whether original (unfiltered/noncentrifuged) ascites may have different miRNA values compared with centrifuged (supernatant fluid) or pelleted cells. To exclude technical bias, we added cel-miR-39 to every sample, similar to what has been done in other experiments for extraction and volume normalization. Generally, all selected miRNAs were detectable in all specimens. As expected, miR-16 and RNU6b were present at the highest levels in the cell pellet and were least abundant in the supernatant fluid (data not shown). After normalization to cel-miR-39, we were able to confirm the highest level in pellets, whereas those miRNAs in the original (ascites as it is without any processing) and the supernatant fluid samples did not demonstrate any differences (Figs. 2E and 2F ). Although the pelleted samples provided the highest values for miRNA expression, the pellets may include not only the malignant cells but also nonneoplastic cells such as leukocytes, erythrocytes, epithelial cells, etc, which can lead to potential nonspecific bias (in a similar fashion as erythrocytes for the whole blood analysis). Because of its simplicity in use and the least risk of preprocessing bias, we further focused on noncentrifuged and nonpelleted original ascites.
miRNA Profiling in Ascites Samples
To further explore the potential of miRNAs to serve as biomarkers in ascites, we performed miRNA expression profiling using TLDA in samples with PCA and compared them with uncomplicated ascites from patients with cirrhosis (characteristics shown in Table 1 ). Several known miRNAs such as miR-16, miR-192, miR-21, and miR-223 were among the top 10 most abundant miRNAs detected. After filtering out miRNAs with low abundance (Ct value >39 in >25% of samples), we retained a set of 43 of 377 miRNAs for further analysis. Next, we normalized the expression levels of the retained miRNAs using 2 different normalization methods: the delta-delta-Ct (using U6 small nuclear RNA [snRNA] as a reference) and the rankinvariant method. After applying 2-class differential expression analysis on U6 snRNA normalized expression values DCT (miR-223) were used to calculate the percentage to discriminate the patients with PCA from those with SBP and to perform the receiver operating characteristic curve analysis. All data are presented as delta threshold cycle (Ct) values normalized to spiked-in cel-miR-39. The Student t test or analysis of variance tests with the Holm-Sidak multiple comparisons post-test with *P <.05; **P <.01; and ***P <.001. CCC indicates cholangiocellular carcinoma; CRC, colorectal cancer; GC, gastric cancer; HCC, hepatocellular carcinoma; NSCLC, non-small cell lung cancer; OC, ovarian cancer; PAC, pancreatic adenocarcinoma.
for the miRNAs, we found miR-186, miR-222, and miR-483-5p to be upregulated in PCA when compared with cirrhosis (Fig. 3A) . Using rank-invariant normalized expression values, we in addition detected miR-21 to be upregulated and miR-26b to be downregulated in PCA when compared with cirrhosis ascites samples (Fig. 3B) .
Validation of Differential miRNA Expression
To validate the results, we performed miRNA expression analysis for miR-21, miR-16, miR-223, miR-186, and miR-122. The selection of the miRNAs was based on the several criteria: frequently deregulated in cancer (miR-21), profiling data (miR-21 and miR-186), frequently used for normalization (miR-16), an association with inflammation and increased expression in PMN (miR-223), and liver specificity (miR-122). In our validation, we enlarged the study groups and also included the samples with SBP ( Figs. 3C and 3D) . Because of the significant correlation between miR-21 and miR-16 (correlation coefficient, 0.8529; P < .0001), we did not use miR-16 for normalization (data not shown). In correlation with the TLDA data, we were able to confirm the significant difference between miR-21 and miR-186 expression in patients with PCA compared with those in the no SBP/PCA groups; however, in the case of SBP, the difference was not statistically significant (eg, miR-21 had a mean 6 standard deviation of 211. . Among the miRNAs examined, the lowest miRNA variation was observed for miR-122 with no difference observed among the groups, suggesting a relatively stable level of expression for this liver-specific miRNA in ascites (data not shown).
As shown in Figure 3 , there was substantial variation in miRNA expression in the PCA cohort. For this reason, we plotted the data for all 4 miRNAs as a heat map (Fig.  3F) . We next sorted the samples in ascending order based on the miR-21 expression. Irrespective of the small number of samples, we observed the highest expression of miRNAs in patients with lung cancer, gastric cancer, and ovarian cancer, whereas the lowest expression was found in patients with pancreatic cancer and hepatocellular carcinoma. This difference leads us to suggest that ascites miRNAs may be influenced by the tumor type.
Because of the substantial overlap in ascites miRNA expression between PCA and SBP, we questioned whether the percentage of certain miRNAs could improve the diagnostic performance. Because miR-21 and miR-186 were confirmed as deregulated miRNAs in PCA and miR-223 was highly upregulated in SBP, we used the percentage of those miRNAs as an example for the potential usefulness of miRNAs as biomarkers. The score was calculated using following formula: 2
DCT (miR-223)
. The score allowed us to differentiate SBP samples with high diagnostic accuracy from PCA samples (Figs. 3G-3J ). The receiver operating characteristic curve analysis demonstrated area under the curve values of 0.982 (95% CI, 0.943-1.022) for miR-21 ( Fig. 3H ) and 0.96 (95% CI, 0.9002-1.02) for miR-186 (Fig. 3J) , further supporting the potential of ascites miRNAs as a potential diagnostic tool in biomarker research.
DISCUSSION
In this proof-of-principle study, we explored the feasibility of miRNA detection in ascites and evaluated the potential use of miRNAs as ascites biomarkers. The results of the current study demonstrated that miRNAs can be easily and reproducibly detected in ascites. Systematic analysis of miRNA stability confirms that miRNAs are well preserved from degradation, suggesting that this tool potentially could be adapted for translational research in future trials. Moreover, profiling and confirmatory analysis have suggested differential expression of miRNAs in peritoneal fluids from patients with different etiologies such as PCA and SBP, further supporting miRNAs as potential biomarkers for malignant and inflammatory diseases.
A substantial amount of data have been collected for miRNAs as noninvasive biomarkers in blood and feces; these data now extend this concept to ascites. [33] [34] [35] In a similar fashion as previously described, we confirmed that miRNAs in ascites demonstrate remarkable stability after drainage under different short-term and long-term storage conditions, similar to the results found with other body fluids and specimens. 34, 36, 37 The fact that miRNAs were detectable in noncentrifuged ascites samples, supernatant fluid, and pellets lead us to believe that not only tumor or
Original Article other cells, but also exosomes and protein complexes, may be the main source of miRNAs in ascites. 21, 24 Therefore, it is not surprising that miRNA concentration was highest in cell pellets and lowest in centrifuged samples. Because of the simplicity and ease of use as well as clinical applicability, we believe that original unprocessed ascites may be the best specimens to work with. Ascites is one of the main symptoms of PCA among malignant diseases. As mentioned in the introduction, the current gold standard in the diagnosis of PCA is cytology or histology, but the limited sensitivity, specifically of cytology, is one of the biggest challenges in clinical settings. [5] [6] [7] The diagnosis of PCA has a substantial prognostic implication for patients and there is an urgent need for alternative approaches to improve the current diagnostic algorithms. Tokuhisa et al recently published an article exploring ascites and peritoneum lavage fluid for miRNA expression in patients with peritoneal metastasis due to gastric cancer. 24 Although the main focus of their study was related to peritoneal lavage fluid, they also included 6 patients with ascites. The results of their study demonstrated that miR-21 and miR-1225-5p were expressed at a significantly higher level in patients with T4 gastric cancer compared with those with T1 to T3 disease. In a similar fashion, we explored the use of TLDA and confirmed the data by TaqMan PCR. We demonstrated that miR-21 and miR-186 expression levels were significantly increased not only in patients with gastric cancer, but overall in patients with PCA when compared with those related to portal hypertension. It is interesting to note that the analysis of the inflammation-related ascites from patients with SBP revealed a slight elevation in miR-21 and miR-186, also in this cohort. Nevertheless, patients with SBP had significantly higher miR-223 expression, which may be helpful in distinguishing them from other noninflammatory ascites groups. Increased expression of miR-223 is not surprising because it is one of the highly expressed miRNAs in PMNs, which are as per definition increased in patients with SBP. This led us to believe that specific miRNA patterns rather than the expression of a single miRNA might be useful as a biomarker. This is supported first by the heat map analysis demonstrating increasing miRNA expression along with increasing miR-21 expression. Second, the evaluation of the ratio between miR-21 and miR-186 compared with miR-223, which was the most expressed miRNA in SBP, allowed us to demonstrate a simple and potential tool for combined miRNA expression analysis.
One of the challenges in miRNA expression analysis is normalization. Multiple previous studies have used miR-16 for the normalization of patient samples, blood, feces, etc. We recently discussed the limitations of using miR-16 for normalization. 19 However, miR-16 remains widely used for this purpose, as noted in the recent study from Tokuhisa et al, which analyzed the peritoneal fluid from patients with gastric cancer. 24 In the current study, we observed a strong correlation between miR-21 and miR-16 expression, suggesting that miR-16 most likely is not suitable for normalization. For this reason, we used spiked-in cel-miR-39 for volume-adjusted and extraction-adjusted normalization.
The current study was performed as part of an exploratory study. Additional high-quality analyses are needed to explore the best approach for miRNA analysis in the future. For example, we mentioned above that there are several forms of ascites specimens that can be used for miRNA evaluation. In the current study, we primarily explored original unprocessed ascites. Although we observed a significant difference in miRNA expression even among the small number of patients in the current study, a more specific source of RNA (eg, exosomal miRNAs) may provide an additional benefit and higher specificity. Another limitation of the current study is the use of TaqMan-based TLDA. The next-generation sequencing of all non-coding RNAs (including long noncoding RNAs etc) could provide a more comprehensive view regarding alterations in ascites.
It also must be mentioned that PCA may be diagnosed for various tumor entities with different frequencies. The largest group of PCA cases in the current study cohort was from pancreatic and gastric cancers, whereas several other entities were represented by 1 case and are rather rare (Table 1) . Therefore, the most frequent tumors may provide somewhat stronger data and create a certain bias, which needs to be taken into account. Nevertheless, we believe that the availability of the "all-cancers" biomarker pattern would make this tool more attractive as a "tumorspecific" pattern. For example, miR-21 has been shown to be upregulated in a majority of tissues and was the preferred target in the current analysis. Finally, we explored the diagnostic potential of miRNA in ascites, although there is the potential for application in therapeutic settings, such as antagomiR (antisense microRNA) or miRNA-like molecules of greater value.
The results of the current study demonstrate that miRNAs can be easily isolated from ascites samples. Ascites miRNAs are well preserved in unprocessed samples with a good short-term and long-term stability, even at room temperature. TLDA profiling and validation analysis revealed several differentially expressed miRNAs in patients with malignant ascites and SBP, suggesting ascites miRNAs as a potential tool for further exploration as biomarkers.
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